The Gist of the "inaccurate" SA article (options are part of the story):
"The most important results on Thursday should be those for the ACLF (Acute on Chronic Liver Failure) phase 2b trial. These results had been anticipated in late 2014 and there has been some concern on the delay. It is a 60 subject trial with the objective of identifying dose for future trials. If the results are positive the stock should jump once again. Negative results will, of course, have the opposite response.
In addition, Conatus will be reporting on Phase 1 trial in patients with mild, moderate and severe hepatic impairment, and Phase 1 trial in patients with severe renal impairment.
Even with today's run-up there may be a good play going into the coming report. Option premiums are again attractive. As I write this one can enter a position for just under $10/share with 17 Apr 2015 call options priced near $4 for a $10 strike and $2.65 for the $12.50 strike. Open interest in both of these stands at 559 and 722 respectively."
Mike, NASDAQ (RUT too) have been heading down since the day after Christmas. We have held our ground until today. Still UGLY everywhere in BIO land (not many exceptions).
Were mostly traded in the $11's, so either those who traded were/are fools or they wanted in that badly for near future reasons. The Nasdaq/Russell were beaten down but we held to a $2 gain overall. Today may be more telling as to what the sentiment really is for Thursday read-out. GLTA
Should be at least $200M which would equate to about $13/shr. IF there is bad news within the presentation (IF) this pre-market trading would be tempered more than it looks. We may see 1M shares traded in the pre-market alone. For those who doubt - sell and take the money off the table!!
So what to expect after all the progress made, the 2 year CF study complete, the EU application response and the almost 20% dilution? Even if all the news/dilution offsets, we would most likely climb above $20 this month (assuming EU acceptance). Time will tell but we are in WAY better shape than 12 months ago with Insmed's prospects.
Adding to this increase in PT by Byrne (BOFA/Merrill Lynch) he just reiterated in November the $9 PT which he lowered in September (I believe). So to increase by 11% his PT he must believe the EU approval (pending) will significantly solidify OREX in the Obesity management sector. So, jd, is "Penny" another one of the trolls hanging out here for some nefarious reason??
This post has a thumbs down for what reason.? They don't even say WILL but just a COULD yet some here see this as something "bad" BOFA is very conservative so this upgrade (PT to $10) is a very good sign for the next 3-6 months.
.search for "eye-popping gains for 2015" OREX is one to watch but not buy just yet. Fool also says EU approval is 2Q 2015 which I think is wrong!
BWD, "Sound in Logic"? For the plethora of Terry IDs/posts? Tax selling is over for those who wanted to use their losses in 2014 which assisted the BIO selloff.
Is this true or is "fly" a year off? Seems to be current from what I could gather!
December 22, 2014
07:24 EDT ECYT Endocyte risk/reward favorable, says RBC Capital
RBC Capital says that Endocyte's stock will rise to $15 in the most likely scenario, while the shares could jump to $31 in a bullish scenario. The firm says the company's Phase III assets have a 65% chance of succeeding.
True ($3k losses a year) but if you were carrying forward a $30K loss from 2013 and were able to gain $30K in 2014, these would then offset in 2014 and you would pay no tax on the gain (which was offset by the loss carried forward). GLTA
Don't remember seeing this one:
Pharmacovigilance Manager/Associate Director
Insmed understands that its most valuable resource is its employees. We place great value on the unique skills, talents and qualities that each of our employees brings to our company. We are building a world-class team with a focus on innovation, teamwork and the desire and ability to change the way our patients live.
Insmed is a fast-paced, high-energy organization that seeks talented individuals who are leaders in their respective functional areas of expertise, who are creative problem solvers and who have the desire to make a difference. This position will initially be based in Monmouth Junction, New Jersey, but as of June 2014 will be based in our new Bridgewater, New Jersey headquarters.
SUMMARY: Reporting to the Vice-President, Regulatory Affairs, this position is responsible for identifying and assisting in the management of safety concerns with the drug product(s) owned by the company.
The Pharmacovigilance Manager/Associate Director ensures that any safety signals are appropriately evaluated, communicated and managed with guidance from supervisor. This role is also responsible for writing documents required for assessment and communication of product safety information for core safety documents.